Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 3
1996 2
1997 1
1998 4
2000 3
2001 3
2002 4
2003 13
2004 16
2005 13
2006 42
2007 29
2008 57
2009 71
2010 90
2011 85
2012 110
2013 114
2014 121
2015 145
2016 182
2017 144
2018 132
2019 119
2020 135
2021 167
2022 132
2023 101
2024 109
2025 122
2026 46

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,056 results

Results by year

Filters applied: . Clear all
Page 1
Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome.
Taub PR, Zadourian A, Lo HC, Ormiston CK, Golshan S, Hsu JC. Taub PR, et al. J Am Coll Cardiol. 2021 Feb 23;77(7):861-871. doi: 10.1016/j.jacc.2020.12.029. J Am Coll Cardiol. 2021. PMID: 33602468 Free article. Clinical Trial.
METHODS: In total, 22 patients with hyperadrenergic POTS as the predominant subtype completed a randomized, double-blinded, placebo-controlled, crossover trial with ivabradine. Patients were randomized to start either ivabradine or placebo for 1 month, and then were …
METHODS: In total, 22 patients with hyperadrenergic POTS as the predominant subtype completed a randomized, double-blinded, placebo-controll …
Ivabradine: cardiovascular effects.
Rognoni A, Bertolazzi M, Macciò S, Rognoni G. Rognoni A, et al. Recent Pat Cardiovasc Drug Discov. 2009 Jan;4(1):61-6. doi: 10.2174/157489009787260016. Recent Pat Cardiovasc Drug Discov. 2009. PMID: 19149708 Review.
The safety of ivabradine has been documented in several studies and clinical trials, in contrast to beta-blockers, no significant side effects were expressed in the literature. The aim of our review is to describe ivabradine and its cardiovascular effects and outlin …
The safety of ivabradine has been documented in several studies and clinical trials, in contrast to beta-blockers, no significant sid …
[Ivabradine].
Sabourin G. Sabourin G. Perspect Infirm. 2011 Jan-Feb;8(1):54. Perspect Infirm. 2011. PMID: 21268387 French. No abstract available.
Structural mechanism of human HCN1 hyperpolarization-activated channel inhibition by ivabradine.
Che T, Zhang W, Cheng X, Lv S, Zhang M, Zhang Y, Yang T, Nan W, Wan S, Zeng B, Li J, Xiong B, Zhang J. Che T, et al. J Biol Chem. 2024 Nov;300(11):107798. doi: 10.1016/j.jbc.2024.107798. Epub 2024 Sep 20. J Biol Chem. 2024. PMID: 39307309 Free PMC article.
Here, we present the cryo-electron microscopy structure of human HCN1 channel in complex with inhibitor ivabradine, the drug on the market that acts on HCN channels. Combining electrophysiology, mutagenesis, and molecular dynamics simulations, our findings reveal that i …
Here, we present the cryo-electron microscopy structure of human HCN1 channel in complex with inhibitor ivabradine, the drug on the m …
Structural determinants of ivabradine block of the open pore of HCN4.
Saponaro A, Krumbach JH, Chaves-Sanjuan A, Sharifzadeh AS, Porro A, Castelli R, Hamacher K, Bolognesi M, DiFrancesco D, Clarke OB, Thiel G, Moroni A. Saponaro A, et al. Proc Natl Acad Sci U S A. 2024 Jul 2;121(27):e2402259121. doi: 10.1073/pnas.2402259121. Epub 2024 Jun 25. Proc Natl Acad Sci U S A. 2024. PMID: 38917012 Free PMC article.
Here, we address the problem by solving the cryo-EM structure of HCN4 in complex with ivabradine, to date the only HCN-specific drug on the market. Our data show ivabradine bound inside the open pore at 3 A resolution. ...Molecular dynamics simulations further revea …
Here, we address the problem by solving the cryo-EM structure of HCN4 in complex with ivabradine, to date the only HCN-specific drug …
Ivabradine curbs isoproterenol-induced kidney fibrosis.
Baka T, Stanko P, Repova K, Aziriova S, Krajcirovicova K, Barta A, Zorad S, Simko F. Baka T, et al. Gen Physiol Biophys. 2023 Mar;42(2):209-215. doi: 10.4149/gpb_2022057. Gen Physiol Biophys. 2023. PMID: 36896950
Twenty-eight Wistar rats were divided into non-diseased controls, rats treated with ivabradine, rats treated with isoproterenol, and rats treated with isoproterenol plus ivabradine. ...We conclude that ivabradine exerts protection against kidney remodelling i …
Twenty-eight Wistar rats were divided into non-diseased controls, rats treated with ivabradine, rats treated with isoproterenol, and …
Ivabradine for treatment of heart failure.
Bocchi EA, Salemi VMC. Bocchi EA, et al. Expert Opin Drug Saf. 2019 May;18(5):393-402. doi: 10.1080/14740338.2019.1612873. Epub 2019 May 10. Expert Opin Drug Saf. 2019. PMID: 31074301 Review.
In chagasic patients, ivabradine reduced HR and a trend toward reduction in all-cause death was observed with ivabradine (p = 0.07). In children with HFrEF, ivabradine increased NYHA functional class. The most common side effects with ivabradine are br …
In chagasic patients, ivabradine reduced HR and a trend toward reduction in all-cause death was observed with ivabradine (p = …
Ivabradine ameliorates doxorubicin-induced cardiotoxicity through improving mitochondrial function and cardiac calcium homeostasis.
Sripusanapan A, Piriyakulthorn C, Apaijai N, Chattipakorn SC, Chattipakorn N. Sripusanapan A, et al. Biochem Pharmacol. 2025 Jun;236:116881. doi: 10.1016/j.bcp.2025.116881. Epub 2025 Mar 18. Biochem Pharmacol. 2025. PMID: 40112930
For in vitro experiments, H9C2 cells were divided into four groups: control, ivabradine (3 muM), Dox (10 muM), and ivabradine co-treated with Dox, with treatments lasting 24 h. ...For in vivo experiments, male rats (n = 6 per group) were divided into control, iva …
For in vitro experiments, H9C2 cells were divided into four groups: control, ivabradine (3 muM), Dox (10 muM), and ivabradine …
Ivabradine for Postoperative JET: Clear for Take-Off?
Janson CM, Clancy CE. Janson CM, et al. JACC Clin Electrophysiol. 2021 Aug;7(8):1061-1063. doi: 10.1016/j.jacep.2021.03.015. JACC Clin Electrophysiol. 2021. PMID: 34412869 Free article. No abstract available.
Ivabradine induces RAD51 degradation, potentiating PARP inhibitor efficacy in non-germline BRCA pathogenic variant triple-negative breast cancer.
Tsoi H, Leung GMH, Man EPS, You CP, Cheung KHL, Chan KYK, Gong C, Huen MSY, Khoo US. Tsoi H, et al. J Transl Med. 2025 Aug 5;23(1):860. doi: 10.1186/s12967-025-06902-8. J Transl Med. 2025. PMID: 40764992 Free PMC article.
Xenografts on nude mice and PDTX were in vivo models for validating the combined effect of ivabradine and olaparib. RESULTS: Using an EGFP-RAD51 reporter, we identified ivabradine as a RAD51-reducing agent. ...Mechanistically, ivabradine triggered ER stress, …
Xenografts on nude mice and PDTX were in vivo models for validating the combined effect of ivabradine and olaparib. RESULTS: Using an …
2,056 results